Diagnostics News and Research RSS Feed - Diagnostics News and Research

Cepheid announces international availability of updated Xpert Carba-R test to identify Superbugs

Cepheid announces international availability of updated Xpert Carba-R test to identify Superbugs

Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. [More]
LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. [More]
GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

In developed countries like the U.S., Europe and parts of Asia, healthcare leaders are trying to optimize efficiency, systems integration, data analytics and achieve greater productivity. In emerging economies, enabling access to affordable, basic primary care is often the most pressing concern. Healthcare systems around the world face a wide range of difficult challenges. All could benefit from training and education solutions focused specifically on their particular needs. [More]
Point-of-care diagnostics for Ebola

Point-of-care diagnostics for Ebola

In a recent DECODED research profile, Integrated DNA Technologies (IDT), details how IDT scientists Kristin Beltz and Dr Scott Rose are collaborating with Dr Brian Taylor’s research team at Battelle (Aberdeen, MD, USA) to design and validate a RT-qPCR assay that can detect the Ebola virus in the field. [More]

Sphere Medical publishes white paper discussing areas where Proxima mitigates sources of pre-analytical errors

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, has published a white paper focusing on the mitigation of common pre-analytical errors associated with arterial blood gas analysis. [More]
Europe has increasing prevalence of fungal resistance, warns ESCMID

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance. [More]
Cepheid, FIND unveil new portable molecular diagnostics system for patients suspected of TB, HIV and Ebola

Cepheid, FIND unveil new portable molecular diagnostics system for patients suspected of TB, HIV and Ebola

Cepheid and FIND today unveiled the GeneXpert Omni, the world's most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world. [More]
IU awarded $4.5 million NIH grant to create new federally designated diabetes research center

IU awarded $4.5 million NIH grant to create new federally designated diabetes research center

The National Institutes of Health has awarded the Indiana University School of Medicine a five-year, $4.5 million grant to create a new federally designated Indiana Diabetes Research Center, one of just 16 such centers in the country. [More]
Simple and accurate detection system can redefine medical diagnostics field

Simple and accurate detection system can redefine medical diagnostics field

In biology and medicine, we often need to detect biological molecules. For example, in cancer diagnostics, doctors need quick and reliable ways of knowing if tumor cells are present in the patient's body. [More]
Abbott, BMW BERLIN-MARATHON partner to celebrate the power of health

Abbott, BMW BERLIN-MARATHON partner to celebrate the power of health

The organizers of the BMW BERLIN-MARATHON today proudly announced a new partnership with the global healthcare company Abbott, which became an Official Sponsor of the 2015 BMW BERLIN-MARATHON, one of six iconic races in the Abbott World Marathon Majors series. [More]
New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancreatitis. The paper, titled "Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models" appears in the August edition of the journal Gastroenterology. [More]
Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical Corporation, the U.S. - based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry Clinical Lab Expo in Atlanta. Three abstracts involve the ReEBOV Ebola rapid diagnostic test (RDT) with a fourth abstract involving the AtherOx™ Assay for assessing heart disease risk. [More]

Quest Diagnostics' second quarter revenue grows by 1.2% to $1.93 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2015, adjusted net income was $170 million compared to $157 million for 2014. Adjusted diluted EPS excluding amortization was $1.25 in the second quarter of 2015, compared to $1.19 in 2014. Amortization expense per diluted share was $0.08 in the second quarter of 2015 and $0.11 in 2014. [More]
Experts to highlight new diagnostic products, tools to identify heart attacks at 2015 AACC Annual Meeting

Experts to highlight new diagnostic products, tools to identify heart attacks at 2015 AACC Annual Meeting

The 2015 AACC Annual Meeting & Clinical Lab Expo, the leading annual event for laboratory medicine, will open on Sunday, July 26, in Atlanta, Georgia. This year's meeting will host more than 400 educational sessions on topics ranging from personalized medicine and infectious diseases to point-of-care and laboratory-developed tests, and will feature more than 200 new cutting edge diagnostic products. [More]
Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Enigma Diagnostics Ltd. and Beijing Leadman Biochemistry Co., Ltd. signed a joint venture agreement with the principal goal of delivering the Enigma MiniLab molecular diagnostic Point-of-Care platform into the Chinese health care market to support its growing diagnostic needs. [More]
Study shows regions of genome underlying IBD consistent around the world

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania. [More]
KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). [More]
Check-Cap provides corporate update, reports financial results for second quarter 2015

Check-Cap provides corporate update, reports financial results for second quarter 2015

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced financial results for the second quarter, ended June 30, 2015. [More]
MD Anderson ranked No. 1 hospital in nation for cancer care

MD Anderson ranked No. 1 hospital in nation for cancer care

The University of Texas MD Anderson Cancer Center has been ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report's "Best Hospitals" survey. [More]
TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

Focus On Lyme, an initiative sponsored by the Leadership Children's Foundation of Gilbert, Ariz., has donated $75,000 to the Translational Genomics Research Institute to support research into the development of a quick, affordable and accurate method of diagnosing Lyme disease. [More]
Advertisement
Advertisement